Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

Dateline City:

KENILWORTH, N.J.

Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that a Phase 2 study of relebactam, the company’s
investigational beta-lactamase inhibitor for the treatment, in
combination with imipenem/cilastatin (an approved carbapenem
antibiotic), of complicated intra-abdominal infections, met its primary
endpoint, and that Merck is now initiating pivotal Phase 3 studies.
Language:

English

Contact:

MerckMedia:Doris Li, [phone]Ian McConnell, [phone]orInvestor:Teri Loxam, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - September 18, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news